title: Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
abstract: BACKGROUND
  Monoclonal antibodies known as biologic agents specifically targeted against interleukin-12 (IL-12), interleukin-17A (IL-17), and interleukin-23 (IL-23) have been the focus of research for moderate-to-severe chronic plaque psoriasis in recent years.
  
  
  OBJECTIVE
  To discuss the immune-mediated model of psoriasis and to summarize current knowledge of the clinical efficacy and safety of new biologic agents for moderate-to-severe chronic plaque psoriasis.
  
  
  METHODS
  The PubMed database was searched for relevant articles on ustekinumab, briakinumab, tildrakizumab (MK-322), guselkumab, secukinumab, ixekizumab, and brodalumab published between January 2005 and July 2013.
  
  
  RESULTS
  Fifty-five articles were identified. These studies suggest that the biologic agents specifically targeting IL-12, IL-17, and IL-23 are efficacious and safe in the treatment of moderate-to-severe psoriasis in adults.
  
  
  CONCLUSIONS
  Current data from clinical trials suggest that biologic agents targeting IL-12, IL-17, and IL-23 are safe and efficacious drugs for use in moderate-to-severe chronic plaque psoriasis. Long-term data still need to be established.
authors.forename: William
authors.initials: W
authors.lastname: Tausend
authors.forename: Christopher
authors.initials: C
authors.lastname: Downing
authors.forename: Stephen
authors.initials: S
authors.lastname: Tyring
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D006801:Humans; D018664:Interleukin-12 / Q000037:antagonists & inhibitors*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; D053759:Interleukin-23; C000588857:guselkumab; D018664:Interleukin-12; C571216:brodalumab; C544528:briakinumab; C549079:ixekizumab; C000598434:tildrakizumab; C555450:secukinumab; D000069549:Ustekinumab